Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3): Beta Plus Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05359146

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:39:49.263433+00:00

Published At

2024-04-19T00:00:00+00:00

Record Updated At

2024-04-19

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Neuroendocrine Neoplasia\u0027s (NENs)", "Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2024-04-19"

protocolSection.identificationModule.nctId

"NCT05359146"

protocolSection.identificationModule.officialTitle

"Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3): Beta Plus Study"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["EARLY_PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Neuroendocrine Neoplasia's (NENs) (protocolSection.conditionsModule.conditions)
• Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.